Lipo-C

Lipo-C is a multi-component "lipotropic" combination preparation typically containing methionine, inositol, choline, and B-complex vitamins (most commonly including cobalamin / B12, and sometimes additional B vitamins such as B1, B2, B5, B6). The "MIC" component (methionine + inositol + choline) is the lipotropic core that gives the preparation its name and research positioning; the B-complex additions provide co-substrates and cofactors for the one-carbon and methyl-cycle biochemistry that underlies the lipotropic concept. Lipo-C preparations have been used in clinical and research contexts since the mid-20th century in the broader category of "lipotropic injections" — combination injectable preparations marketed for purported support of hepatic lipid metabolism and broader metabolic-research applications.

This research-supply preparation is supplied as an aqueous combination preparation for research-supply use. Specific component concentrations, ratios, and the specific B-complex composition appear on the supplier's certificate of analysis for the particular lot. The preparation is studied in research-supply context as a standardized multi-component lipotropic tool rather than as separate single-component reconstitution and combination.

This page is a research-only educational reference. The preparation is supplied as a research-supply product for laboratory and research-supply use and is not intended for human consumption or any therapeutic application. No medical claims are made on this page.

Lipo-C is named for its lipotropic combination composition. The "MIC" core consists of:

Methionine (L-methionine). An essential sulfur-containing amino acid that serves as the precursor of S-adenosyl-L-methionine (SAM), the universal cellular methyl donor for transmethylation reactions including DNA and histone methylation, phosphatidylethanolamine-to-phosphatidylcholine conversion (via PEMT, phosphatidylethanolamine N-methyltransferase), creatine synthesis, and many other methyl-transfer reactions. Methionine is also the entry point of the transsulfuration pathway leading to cysteine and ultimately glutathione synthesis.

Inositol (typically myo-inositol). A cyclic six-carbon polyol (a cyclitol) that is the precursor of phosphoinositide lipids, which function as second messengers in cellular signaling (PIP2, PIP3, IP3 / DAG signaling) and as structural components of cell membranes. Myo-inositol is also a component of inositol-phosphate and inositol-pyrophosphate signaling systems and a contributor to cellular osmotic regulation.

Choline (typically choline chloride or choline bitartrate). A quaternary ammonium compound that is the precursor of phosphatidylcholine (the principal mammalian membrane phospholipid), sphingomyelin, acetylcholine, and betaine (an osmolyte and methyl donor). Choline can also be synthesized endogenously from phosphatidylethanolamine via the PEMT methylation reaction (which requires methionine-derived SAM).

The B-complex additions typically include cobalamin (B12, methionine-cycle cofactor), folate (B9, one-carbon-cycle cofactor), and pyridoxine (B6, transsulfuration cofactor), all of which support the methyl-cycle and transsulfuration biochemistry that underlies the lipotropic concept. Specific B-complex composition varies among Lipo-C formulations; refer to the supplier's certificate of analysis for the specific composition.

The lipotropic concept emerged from mid-20th-century research on dietary factors influencing hepatic lipid handling. The classical observation was that diets deficient in methionine, choline, or related methyl-cycle nutrients produced hepatic lipid accumulation ("fatty liver") in rodent models, and that supplementation with methionine, choline, and inositol could prevent or reverse the lipid accumulation. The mechanistic understanding centers on the role of these nutrients in phosphatidylcholine biosynthesis required for hepatic VLDL assembly and secretion: hepatic export of lipid as VLDL particles requires PC for the particle's outer leaflet, and dietary methyl-donor and choline insufficiency impairs PC supply and VLDL secretion, producing hepatic lipid accumulation.

This is a multi-component research-supply preparation, not a peptide. It is supplied for laboratory and research-supply use in metabolic and hepatic research and is not intended for human consumption or any therapeutic application.

The lipotropic concept was developed in the 1930s-1950s through experimental nutrition research on hepatic lipid metabolism. Charles Best and James Collip (best known for insulin) and subsequent investigators characterized the development of fatty liver in rodents fed diets deficient in choline, methionine, or related methyl-cycle nutrients, and characterized the prevention of this fatty-liver phenotype with supplementation. The work established the term "lipotropic" — literally "fat-acting" — for nutrients that prevent abnormal hepatic lipid accumulation.

The biochemical basis of the lipotropic effect was characterized over subsequent decades. The principal axis is phosphatidylcholine biosynthesis: hepatic export of triglyceride-rich VLDL particles requires phosphatidylcholine for the particle's outer leaflet, and PC biosynthesis depends on the choline (CDP-choline pathway) and methionine / SAM (PEMT pathway) supply. Insufficient methyl-donor and choline supply impairs PC synthesis, impairs VLDL assembly and secretion, and produces hepatic triglyceride accumulation — the classical "fatty liver" of methyl-donor-deficient diets. Inositol supports the PI / phosphoinositide-lipid biosynthesis pathway and contributes to hepatic lipid handling through related mechanisms.

The translation of the lipotropic concept to combination injectable preparations ("lipotropic injections") occurred in mid-20th-century clinical practice. The preparations have been used in various weight-management and metabolic-research contexts for several decades, with mixed empirical support in controlled clinical research. The compositional variability of "lipotropic" preparations across manufacturers, clinical sites, and time periods has been substantial; the specific compositional choices for any particular Lipo-C preparation reflect the formulator's specific design.

In research-supply contexts, multi-component lipotropic preparations are used as standardized combination tools for metabolic and hepatic research, with the specific composition documented on the supplier's certificate of analysis.

The three core MIC components and the B-complex additions engage interconnected biochemistry centered on one-carbon metabolism, phospholipid biosynthesis, and hepatic lipid handling.

Methionine and the methyl cycle. Methionine is converted to S-adenosyl-L-methionine (SAM) by methionine adenosyltransferase. SAM is the universal methyl donor for transmethylation reactions including the PEMT phosphatidylcholine synthesis pathway (PEMT methylates phosphatidylethanolamine three times sequentially to produce phosphatidylcholine, consuming three SAM equivalents per PC molecule). The PEMT pathway accounts for approximately 30% of hepatic PC synthesis under fed conditions and is essential for normal hepatic VLDL secretion. Methylation reactions produce S-adenosyl-L-homocysteine (SAH), which is hydrolyzed to homocysteine. Homocysteine can be remethylated to methionine (using methylcobalamin-dependent methionine synthase with 5-methyltetrahydrofolate or betaine-dependent BHMT with betaine as methyl donor) or can enter the transsulfuration pathway (via pyridoxine-dependent cystathionine β-synthase) to produce cysteine and ultimately glutathione.

Inositol and phosphoinositide lipids. Myo-inositol is the precursor of phosphatidylinositol (PI), which is sequentially phosphorylated to PIP, PIP2, and PIP3. The phosphoinositides serve as second messengers in cellular signaling and as anchors for various membrane-associated proteins. Inositol-phosphate signaling (IP3 / DAG produced by phospholipase C cleavage of PIP2) is the canonical inositol second-messenger system. Inositol also contributes to hepatic lipid handling through phosphatidylinositol incorporation into lipoprotein particles and through inositol-pyrophosphate regulation of cellular metabolic enzymes.

Choline biosynthesis and metabolism. Dietary choline is converted to phosphatidylcholine by the CDP-choline pathway (choline → phosphocholine → CDP-choline → phosphatidylcholine, with the rate-limiting step being CTP:phosphocholine cytidylyltransferase). Choline is also oxidized to betaine (in mitochondria, by choline dehydrogenase), which serves as a methyl donor for the BHMT-mediated alternative pathway of homocysteine remethylation. Endogenous choline biosynthesis from phosphatidylethanolamine via PEMT provides a methionine/SAM-dependent alternative to dietary choline.

B-complex cofactors. Cobalamin (B12) is the cofactor for methionine synthase and methylmalonyl-CoA mutase. Folate (B9) supports the one-carbon cycle (5,10-methylene-THF and 5-methyl-THF are the principal one-carbon-carrying folate species). Pyridoxine (B6) is the cofactor for cystathionine β-synthase and cystathionine γ-lyase in the transsulfuration pathway and for many aminotransferases. Riboflavin (B2) is the cofactor for methylenetetrahydrofolate reductase (MTHFR) and many other flavoprotein enzymes. Thiamine (B1) is the cofactor for pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, and transketolase. Pantothenic acid (B5) is the precursor of coenzyme A. The specific B-complex composition of a Lipo-C preparation determines which of these cofactor systems are supplemented; refer to the supplier's certificate of analysis for the specific composition.

Hepatic lipid handling. The integration of the three MIC components with the B-complex cofactors supports hepatic phosphatidylcholine biosynthesis (via both the CDP-choline pathway from dietary choline and the PEMT pathway from methionine / SAM), which in turn supports hepatic VLDL assembly and secretion of triglyceride from the liver. Deficiency in methyl-donor or choline supply impairs PC biosynthesis, impairs VLDL secretion, and produces hepatic triglyceride accumulation. The "lipotropic" concept positions combination preparations of these nutrients as research-supply or clinical tools supporting hepatic lipid handling. The empirical clinical support for lipotropic-injection interventions in human weight-management contexts is limited and inconsistent in controlled trials.

Lipo-C is a multi-component aqueous preparation. The chemical character of each component:

Methionine (L-Met): essential sulfur-containing amino acid; molecular formula C5H11NO2S; MW 149.21 g/mol. The L-enantiomer is the biologically active form. Highly water-soluble; stable as zwitterion at physiological pH.

Myo-inositol: cyclic six-carbon polyol; molecular formula C6H12O6; MW 180.16 g/mol. Nine possible stereoisomers exist; myo-inositol is the predominant naturally occurring form. Highly water-soluble.

Choline (typically choline chloride): quaternary ammonium compound; molecular formula C5H14ClNO; MW 139.62 g/mol for choline chloride (~104 g/mol for the choline cation). Highly hygroscopic and water-soluble.

B-complex additions vary in chemical character. Cobalamin (~1,355 Da for cyanocobalamin), folate (~441 Da for folic acid), pyridoxine (~169 Da), riboflavin (~376 Da), thiamine (~265 Da), and pantothenic acid (~219 Da) cover a substantial molecular-weight range. All are water-soluble and stable in appropriately formulated aqueous preparations.

The specific concentrations of each component in a Lipo-C preparation depend on the formulator's specific design. The total component composition appears on the supplier's certificate of analysis. The combination preparation is typically pH-adjusted and may include buffering excipients to support stability of the multi-component mixture.

Storage of multi-component aqueous lipotropic preparations is typically at refrigerated temperature (2-8°C) protected from light, with shelf-life specifications based on stability data for the specific formulation. The B-vitamin components (particularly riboflavin and cobalamin) are photolabile and require light protection.

Published research using methionine-inositol-choline-B-complex combinations and the analogous research-supply applications for Lipo-C preparations include:

Hepatic lipid-handling research. Rodent models of hepatic steatosis (high-fat-diet-induced, methionine-choline-deficient-diet-induced, alcohol-induced) are studied with methionine, choline, and combined lipotropic supplementation to characterize effects on hepatic triglyceride content, VLDL secretion, hepatic PC content, and hepatic gene-expression profiles relevant to lipid metabolism. The methionine-choline-deficient (MCD) diet model is a foundational tool in NAFLD / NASH research and provides the experimental basis for the lipotropic-supplementation research paradigm.

Phosphatidylcholine biosynthesis pathway research. Cultured hepatocytes (primary and immortalized HepG2 and Huh7 lines) and rodent liver tissue are studied to characterize the CDP-choline and PEMT pathways of PC biosynthesis under varying methyl-donor and choline availability. Combination supplementation provides a research-context tool for restoring both pathway substrates simultaneously.

One-carbon metabolism and methyl-cycle research. The integrated methionine / SAM / homocysteine cycle and its connections to folate one-carbon metabolism, B12-dependent methyl transfer, and transsulfuration glutathione synthesis are studied with combined supplementation of methionine and B-complex cofactors. Epigenetic methylation, redox biology, and amino-acid metabolism intersect in this research area.

Cell-culture media supplementation. Custom cell-culture media formulations using defined methionine, inositol, choline, and B-complex content are studied for effects on cell growth, lipid composition, and specific metabolic phenotypes.

Comparative-formulation research. Studies comparing the effects of single-component supplementation (methionine alone, choline alone, B12 alone) with multi-component combination supplementation in matched experimental conditions provide research-context information on the contribution of each component to observed phenotypes.

Hepatic VLDL secretion research. The contribution of phosphatidylcholine biosynthesis to hepatic VLDL particle assembly and secretion is studied in cell-culture and rodent models with combined lipotropic supplementation as a research-context intervention.

All applications are research-supply context: laboratory and research-supply use in cells, isolated tissues, and rodent in-vivo studies. The preparation is not for human consumption. Nothing on this page describes a clinical protocol or therapeutic use.

Lipo-C sits within the family of lipotropic and combination metabolic-research preparations. The principal alternatives are the individual single-component preparations and other combination formulations.

Lipo-C is a multi-component lipotropic combination preparation containing methionine, inositol, choline (the MIC core), and B-complex vitamins (commonly cobalamin and others). The lipotropic concept emerged from mid-20th-century rodent research on the prevention of hepatic lipid accumulation by combinations of methyl-donor and choline nutrients. The biochemical basis centers on phosphatidylcholine biosynthesis, which is required for hepatic VLDL particle assembly and secretion of triglyceride from the liver. The B-complex additions provide cofactors (cobalamin for methionine synthase, folate for one-carbon metabolism, pyridoxine for transsulfuration, others) that support the underlying methyl-cycle and transsulfuration biochemistry.

In research-supply context, Lipo-C is studied as a standardized multi-component lipotropic tool in hepatic lipid-handling research, phosphatidylcholine biosynthesis pathway research, one-carbon metabolism and methyl-cycle research, and combination-pharmacology research with other metabolic compounds. The methionine-choline-deficient (MCD) rodent diet model is the foundational experimental basis for the lipotropic-supplementation research paradigm.

The preparation is supplied as a research-supply product for laboratory and research-supply use, not as a medicine and not for human consumption. The educational content on this page provides scientific and historical context for the research-supply application only. Specific component composition and concentrations appear on the supplier's certificate of analysis for the specific lot.